Therapy of diffuse large B-cell lymphomas

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 386-387

  Pfreundschuh, M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; LARGE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 70349088538     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70059-0     Document Type: Article

References (9)

1. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
3. Pfreundschuh M., Truemper L., Oesterborg A., et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: results of an open-label randomized trial of the Mabthera International Trial (MInT) Study Group. Lancet Oncol 7 (2006) 379-391
4. Persky D.O., Unger J.M., Spier C.M., et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26 (2008) 2258-2263
5. Glass B., Kloess M., Bentz M., et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107 (2006) 3058-3064
6. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641
7. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
8. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
9. Pfreundschuh M., Zeynalova S., Poeschel V., et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group [abstract]. Ann Oncol 19 (2008) 99-100